Pernix Therapeutics Holdings Inc (PTX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9838)
◆英語タイトル:Pernix Therapeutics Holdings Inc (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9838
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:71
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Pernix Therapeutics Holdings Inc (Pernix Therapeutics) is a specialty pharmaceutical company that discovers, develops, and markets generic pharmaceutical products. The company’s portfolio encompasses a fixed dose combination product prescribed to treat acute migraine; an extended-release (XR) opioid agonist that is indicated for pain severe management, and long-term opioid treatment; a non-narcotic, non-addictive, and non-scheduled prescription sleep aid to treat insomnia; an antibiotic for infections of middle ear; and indications for depressive disorder in adults. Its branded and generic pharmaceuticals products span the therapeutic areas of neurology, psychiatry, and pain management. The company serves drug wholesalers, retail drug stores, and mass merchandisers. It has subsidiaries in the US and Ireland. Pernix Therapeutics is headquartered in Morristown, New Jersey, the US.

Pernix Therapeutics Holdings Inc (PTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pernix Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Pernix Therapeutics Acquires Rights to Contrave/Mysimba from Orexigen Therapeutics for USD75 Million 13
Pernix Acquires Zohydro ER Business from Zogenix 14
Pernix Therapeutics Completes Acquisition of Treximet Tablets For Migraine From GlaxoSmithKline 16
Partnerships 18
Pernix Therapeutics Enters Into Co-Promotion Agreement With Osmotica Pharma For Khedezla ER Tablets 18
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 19
Somaxon Pharma Enters Into Co-Marketing Agreement With CJ CheilJedang For Silenor 20
Particle Sciences Enters Into Co-Development Agreement With Pernix Therapeutics 21
Pernix Therapeutics Enters Into Co-Development Agreement For Pediatric Product 22
Licensing Agreements 23
Pernix Therapeutics Enters into Licensing Agreement with Recro Pharma 23
Pernix Therapeutics Enters Into Licensing Agreement For Prescription Product To Treat Gastroenterology Disease 24
Equity Offering 25
Pernix Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 25
Pernix Therapeutics Plans to Raise Funds through Public Offering of Shares 26
Pernix Therapeutics to Raise up to USD16 Million in Public Offering of Shares 27
Somaxon Pharma Completes Private Placement Of Shares For US$3 Million 28
Pernix Therapeutics Completes Public Offering Of Shares For US$21.3 Million 29
Debt Offering 31
Pernix Therapeutics Raises USD130 Million in Private Placement of 4.25% Notes Due 2021 31
Pernix Therapeutics Holdings Raises USD65 Million in Private Palcement of 8% Notes Due 2019 33
Pernix Therapeutics Holdings Raises USD220 Million in Private Placement of Notes 34
Pernix Therapeutics Completes Private Placement Of Notes Due 2019 For US$65 Million 35
Asset Transactions 36
SI Pharma Acquires Cedax from Pernix Therapeutics 36
Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For US$30 Million 37
Acquisition 38
Pernix Therapeutics May Sell Itself 38
Woodfield Pharma Acquires Pernix Manufacturing From Pernix Therapeutics For US$6.2 Million 39
Pernix Therapeutics Completes Acquisition Of Somaxon Pharma For US$25 Million 40
Pernix Therapeutics Completes Acquisition Of Cypress Pharma And Hawthorn Pharma For US$102 Million 42
Pernix Therapeutics Completes Acquisition Of Great Southern Laboratories For US$6 Million 43
Pernix Therapeutics Holdings Inc – Key Competitors 44
Pernix Therapeutics Holdings Inc – Key Employees 45
Pernix Therapeutics Holdings Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
Aug 09, 2018: Pernix Therapeutics reports second quarter 2018 financial results 47
May 10, 2018: Pernix Therapeutics Reports First Quarter 2018 Financial Results 50
Mar 08, 2018: Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 51
Nov 07, 2017: Pernix Therapeutics Reports Third Quarter 2017 Financial Results 54
Jul 27, 2017: Pernix Therapeutics Reports Second Quarter 2017 Financial Results and Provides Business Update 57
Jul 20, 2017: Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results 60
May 15, 2017: Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update 62
Mar 28, 2017: Pernix Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results 64
Corporate Communications 68
Feb 06, 2018: Pernix Announces Appointment of Lead Independent Director and Key Management Team Promotion 68
Nov 16, 2017: Pernix Therapeutics Announces Election of Two Healthcare Industry Veterans to Board of Directors 69
Oct 17, 2017: Pernix Therapeutics Announces Planned Departure of Chief Financial Officer 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pernix Therapeutics Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Pernix Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Pernix Therapeutics Acquires Rights to Contrave/Mysimba from Orexigen Therapeutics for USD75 Million 13
Pernix Acquires Zohydro ER Business from Zogenix 14
Pernix Therapeutics Completes Acquisition of Treximet Tablets For Migraine From GlaxoSmithKline 16
Pernix Therapeutics Enters Into Co-Promotion Agreement With Osmotica Pharma For Khedezla ER Tablets 18
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 19
Somaxon Pharma Enters Into Co-Marketing Agreement With CJ CheilJedang For Silenor 20
Particle Sciences Enters Into Co-Development Agreement With Pernix Therapeutics 21
Pernix Therapeutics Enters Into Co-Development Agreement For Pediatric Product 22
Pernix Therapeutics Enters into Licensing Agreement with Recro Pharma 23
Pernix Therapeutics Enters Into Licensing Agreement For Prescription Product To Treat Gastroenterology Disease 24
Pernix Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 25
Pernix Therapeutics Plans to Raise Funds through Public Offering of Shares 26
Pernix Therapeutics to Raise up to USD16 Million in Public Offering of Shares 27
Somaxon Pharma Completes Private Placement Of Shares For US$3 Million 28
Pernix Therapeutics Completes Public Offering Of Shares For US$21.3 Million 29
Pernix Therapeutics Raises USD130 Million in Private Placement of 4.25% Notes Due 2021 31
Pernix Therapeutics Holdings Raises USD65 Million in Private Palcement of 8% Notes Due 2019 33
Pernix Therapeutics Holdings Raises USD220 Million in Private Placement of Notes 34
Pernix Therapeutics Completes Private Placement Of Notes Due 2019 For US$65 Million 35
SI Pharma Acquires Cedax from Pernix Therapeutics 36
Breckenridge Pharma Completes Acquisition of Certain Generic Assets From Pernix Therapeutics For US$30 Million 37
Pernix Therapeutics May Sell Itself 38
Woodfield Pharma Acquires Pernix Manufacturing From Pernix Therapeutics For US$6.2 Million 39
Pernix Therapeutics Completes Acquisition Of Somaxon Pharma For US$25 Million 40
Pernix Therapeutics Completes Acquisition Of Cypress Pharma And Hawthorn Pharma For US$102 Million 42
Pernix Therapeutics Completes Acquisition Of Great Southern Laboratories For US$6 Million 43
Pernix Therapeutics Holdings Inc, Key Competitors 44
Pernix Therapeutics Holdings Inc, Key Employees 45
Pernix Therapeutics Holdings Inc, Subsidiaries 46

List of Figures
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pernix Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pernix Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Pernix Therapeutics Holdings Inc (PTX):製薬・医療:M&Aディール及び事業提携情報(Pernix Therapeutics Holdings Inc (PTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆